Investors & Media

Press Releases

Date Title and Summary Additional Formats
Toggle Summary ImmunoGen Presents Final Data From Phase 1b FORWARD II Triplet Cohort Evaluating Mirvetuximab Soravtansine in Combination With Carboplatin and Avastin® at ESMO
Triplet Combination Demonstrates Encouraging Anti-Tumor Activity and Tolerability in Recurrent Platinum-Sensitive Ovarian Cancer WALTHAM, Mass. --(BUSINESS WIRE)--Sep. 17, 2020-- ImmunoGen, Inc. , (Nasdaq: IMGN) a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of
View HTML
Toggle Summary ImmunoGen Announces Webcast of Presentation at Upcoming H.C. Wainwright Virtual Global Investment Conference
WALTHAM, Mass. --(BUSINESS WIRE)--Sep. 2, 2020-- ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that Susan Altschuller , Chief Financial Officer, and Anna Berkenblit , Chief Medical Officer, will
View HTML
Toggle Summary ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
WALTHAM, Mass. --(BUSINESS WIRE)--Sep. 1, 2020-- ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that on August 31, 2020 the compensation committee of the Company’s Board of Directors granted
View HTML
Toggle Summary ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
WALTHAM, Mass. --(BUSINESS WIRE)--Aug. 3, 2020-- ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that on July 31, 2020 the compensation committee of the Company’s Board of Directors granted non-qualified
View HTML
Toggle Summary ImmunoGen Reports Recent Progress and Second Quarter 2020 Financial Results
Encouraging Data from FORWARD II Study of Mirvetuximab in Combination with Avastin ® in Recurrent Ovarian Cancer, Regardless of Platinum Status, Presented at ASCO Preclinical Data on Next Generation Anti-FRα ADC, IMGN151, Demonstrating Enhanced Anti-Tumor Activity, Presented at AACR Positive
View HTML
Toggle Summary ImmunoGen Announces Webcast of Presentation at Upcoming Canaccord Genuity Virtual Growth Conference
WALTHAM, Mass. --(BUSINESS WIRE)--Jul. 29, 2020-- ImmunoGen, Inc. , (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that Anna Berkenblit , Chief Medical Officer, will participate in a fireside chat at the upcoming 40 th
View HTML
Toggle Summary ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
WALTHAM, Mass. --(BUSINESS WIRE)--Jul. 22, 2020-- ImmunoGen Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that in connection with the appointment of Susan Altschuller , PhD as ImmunoGen’s Senior Vice President
View HTML
Toggle Summary ImmunoGen Appoints Susan Altschuller, PhD as Senior Vice President and Chief Financial Officer
WALTHAM, Mass. --(BUSINESS WIRE)--Jul. 20, 2020-- ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that Susan Altschuller , PhD has been appointed Senior Vice President and Chief Financial Officer.
View HTML
Toggle Summary ImmunoGen Announces Conference Call to Discuss Its Second Quarter 2020 Operating Results
WALTHAM, Mass. --(BUSINESS WIRE)--Jul. 16, 2020-- ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the Company will host a conference call at 8:00 a.m.
View HTML
Toggle Summary ImmunoGen Presents Preclinical Data on IMGN151 at Virtual AACR Annual Meeting
Next Generation FRα-Targeting ADC Engineered to Maximize Potential Clinical Benefit for Patients with Lower FRα Expression Potent Anti-Tumor Activity Exhibited in Ovarian Cancer and Other Tumor Types Regardless of FRα Expression Level WALTHAM, Mass. --(BUSINESS WIRE)--Jun.
View HTML